Latest Insider Transactions at Igm Biosciences, Inc. (IGMS)
This section provides a real-time view of insider transactions for Igm Biosciences, Inc. (IGMS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IGM Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IGM Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+1.58%
|
$1,900
$1.39 P/Share
|
|
Jul 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,253
-22.55%
|
$111,517
$89.43 P/Share
|
|
Jul 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+31.03%
|
$0
$0.93 P/Share
|
|
Jun 30
2021
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
130
+11.8%
|
-
|
|
Jun 30
2021
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
211
+10.24%
|
-
|
|
Jun 30
2021
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
300
+50.0%
|
-
|
|
Jun 30
2021
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
195
+0.54%
|
-
|
|
Jun 30
2021
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
130
+0.23%
|
-
|
|
Jun 30
2021
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
130
+0.0%
|
-
|
|
Jun 02
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
941
-0.8%
|
$74,339
$79.15 P/Share
|
|
Jun 02
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,245
-28.94%
|
$98,355
$79.15 P/Share
|
|
Jun 01
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
959
-0.81%
|
$75,761
$79.99 P/Share
|
|
Jun 01
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+1.58%
|
$1,900
$1.39 P/Share
|
|
Jun 01
2021
|
Julie Hambleton |
SELL
Open market or private sale
|
Direct |
2,000
-40.0%
|
$160,000
$80.0 P/Share
|
|
Jun 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,255
-22.58%
|
$99,145
$79.99 P/Share
|
|
Jun 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+31.03%
|
$0
$0.93 P/Share
|
|
May 26
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
444
-0.38%
|
$31,080
$70.0 P/Share
|
|
May 14
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
456
-0.39%
|
$31,008
$68.76 P/Share
|
|
May 14
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+0.76%
|
$900
$1.39 P/Share
|
|
May 14
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
288
+8.61%
|
$12,960
$45.9 P/Share
|
|
May 14
2021
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
313
+15.55%
|
$14,085
$45.9 P/Share
|
|
May 14
2021
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
45
+0.8%
|
$2,025
$45.9 P/Share
|
|
May 05
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
469
-0.4%
|
$29,078
$62.32 P/Share
|
|
May 05
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,243
-30.98%
|
$77,066
$62.5 P/Share
|
|
May 03
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
481
-0.41%
|
$32,708
$68.03 P/Share
|
|
May 03
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
950
+0.8%
|
$950
$1.39 P/Share
|
|
May 03
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,257
-23.86%
|
$85,476
$68.03 P/Share
|
|
May 03
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+32.18%
|
$0
$0.93 P/Share
|
|
Apr 12
2021
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
300
+2.31%
|
-
|
|
Apr 12
2021
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
300
-100.0%
|
-
|
|
Apr 06
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,222
-1.04%
|
$100,204
$82.0 P/Share
|
|
Apr 06
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,254
-31.17%
|
$102,828
$82.0 P/Share
|
|
Apr 05
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
678
-0.57%
|
$56,274
$83.4 P/Share
|
|
Apr 05
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+1.58%
|
$1,900
$1.39 P/Share
|
|
Apr 05
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-23.65%
|
$103,418
$83.4 P/Share
|
|
Apr 05
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+32.18%
|
$0
$0.93 P/Share
|
|
Mar 31
2021
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
130
+13.37%
|
-
|
|
Mar 31
2021
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
211
+0.22%
|
-
|
|
Mar 31
2021
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
195
+0.54%
|
-
|
|
Mar 31
2021
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
130
+0.23%
|
-
|
|
Mar 31
2021
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
300
+50.0%
|
-
|
|
Mar 31
2021
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
130
+0.0%
|
-
|
|
Mar 05
2021
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+33.16%
|
$2,750
$1.39 P/Share
|
|
Mar 02
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,224
-1.04%
|
$110,160
$90.25 P/Share
|
|
Mar 02
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,619
-36.9%
|
$145,710
$90.25 P/Share
|
|
Mar 01
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
676
-0.57%
|
$62,192
$92.44 P/Share
|
|
Mar 01
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+1.58%
|
$1,900
$1.39 P/Share
|
|
Mar 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
881
-16.72%
|
$81,052
$92.44 P/Share
|
|
Mar 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+32.18%
|
$0
$0.93 P/Share
|
|
Feb 03
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,226
-1.04%
|
$117,696
$96.0 P/Share
|